Second Life Creator Linden Lab Prepares To Test Parallel VR Universe

support Project Sansar.

Linden plans to make it easy for Second Life denizens to migrate their virtual activities to Project Sansar. But the alternate virtual world will have new features, and will operate by somewhat different rules.

Altberg says the company is looking to scale up on a number of fronts, including the size of events that can be held in Project Sansar, the number of avatars participating, and the amount of money users can make through their projects.

For example, Linden wants users to be able to make an unlimited number of “copies” of profitable constructs they’ve created. If an entrepreneur builds a virtual chemistry lab for a college class, that lab could also be sold to other colleges that want to teach chemistry, Altberg says.

Competition within the virtual community might heat up in Project Sansar, because Linden wants to lower the barriers to entry for creators and entrepreneurs. The company is working on tools to make it easier to build something for advanced virtual reality hardware without being a professional developer. It’s also changing its revenue model.

Rather than making most of its money renting land, Linden would make land cheaper, but charge taxes on users’ revenues from in-world businesses once they’ve succeeded. This could open up the site to new kinds of businesses, Altberg says.

“Some businesses in Second Life may not have the same success in Sansar,” Altberg says.

Author: Bernadette Tansey

Bernadette Tansey is a former editor of Xconomy San Francisco. She has covered information technology, biotechnology, business, law, environment, and government as a Bay area journalist. She has written about edtech, mobile apps, social media startups, and life sciences companies for Xconomy, and tracked the adoption of Web tools by small businesses for CNBC. She was a biotechnology reporter for the business section of the San Francisco Chronicle, where she also wrote about software developers and early commercial companies in nanotechnology and synthetic biology.